Study of Cell Transplantation in Medicare Multiple Myeloma Subjects

The University of Virginia Cancer Center seeks adults ages 18 or older for a research study that collects information about Multiple Myeloma and cell transplantation. This study will compare outcomes between patients who receive allogeneic hematopoietic cell transplantation (alloHCT) for their disease and patient who receive standard treatment. You may be able to participate in this study if you are:
- a Medicare beneficiary,
- have Stage II or III multiple myeloma, and
- will receive an allogeneic stem cell transplant in the US.

By participating in this study, Medicare may pay for your stem cell transplant. The study will collect data on participants health for up to 5 years.